Charles Schwab’s OnKure Therapeutics OKUR Stock Holding History

Charles Schwab’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,750	Closed	-$62.3K	–	3690
2024 Q1	$62.3K	Hold	3,750	–	–	﹤0.01%	3347
2023 Q4	$60K	Hold	3,750	–	–	﹤0.01%	3387
2023 Q3	$286K	Buy	3,750 +795	+27%	+$54.1K	﹤0.01%	3227
2023 Q2	$194K	Buy	+2,955	New	+$238K	﹤0.01%	3311
2022 Q2	–	Sell	-1,883	Closed	-$56K	–	3663
2022 Q1	$56K	Hold	1,883	–	–	﹤0.01%	3513
2021 Q4	$161K	Buy	1,883 +546	+41%	+$40.1K	﹤0.01%	3389
2021 Q3	$100K	Hold	1,337	–	–	﹤0.01%	3382
2021 Q2	$125K	Buy	+1,337	New	+$149K	﹤0.01%	3285

Other funds holding OKUR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Charles Schwab's OKUR Position: Q2 2024 in Review

Charles Schwab sold out of OnKure Therapeutics (OKUR) in Q2 2024, closing a stake of 3,750 shares — an estimated $62.3K sold.

Charles Schwab first reported a position in OKUR in Q2 2021 and held it in 8 quarters. The position peaked at $286K in Q3 2023. 66 funds tracked by Wall St. Rank hold OKUR as of Q2 2024.

Charles Schwab reported no remaining OnKure Therapeutics position as of Q2 2024 after selling out during the quarter.
Charles Schwab sold 3,750 OnKure Therapeutics shares in Q2 2024, an estimated $62.3K.
Charles Schwab first reported a position in OnKure Therapeutics in Q2 2021 and held it in 8 quarters.
Charles Schwab's OnKure Therapeutics position peaked at $286K in Q3 2023.
66 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.